|
|
| (36 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[COVID-19 Pulmonary Complications]] |
| To go to the COVID-19 project topics list, click '''[[COVID-19 Project Topics|here]]'''.
| |
| | |
| {{CMG}} {{AE}} {{S.M.}}
| |
| ==Overview==
| |
| | |
| ==Complications==
| |
| | |
| ===Acute respiratory distress syndrome===
| |
| *
| |
| | |
| ===Pneumonia===
| |
| | |
| ===Pulmonary embolism===
| |
| | |
| ===Hypoxemia===
| |
| | |
| ===Superinfection===
| |
| | |
| ===Respiratory failure===
| |
| | |
| ===Increased mortality in COPD patients===
| |
| *According to a study conducted in China, having an underlying comorbidity such as chronic obstructive pulmonary disease (COPD) conferred a mortality hazard ratio of 2.681, even after adjusting for smoking status.<ref name="pmid32217650">{{cite journal| author=Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM | display-authors=etal| title=Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. | journal=Eur Respir J | year= 2020 | volume= 55 | issue= 5 | pages= | pmid=32217650 | doi=10.1183/13993003.00547-2020 | pmc=7098485 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32217650 }} </ref>
| |
| | |
| ==References==
| |